铂耐药卵巢癌的治疗进展  

Progress in the treatment of platinum-resistant ovarian cancer

作　　者：孙霖 苏跃 耿海涛[1] 李绵利[1] SUN Lin;SU Yue;GENG Haitao;LI Mianli(Department of Oncology,Affiliated Hospital of Binzhou Medical College,Binzhou Shandong 256603)

机构地区：[1]滨州医学院附属医院肿瘤科,山东滨州256603

出　　处：《当代医药论丛》2023年第11期18-22,共5页

基　　金：省部级课题:山东省医学会-齐鲁专项基金,编号:YXH2022ZX02153。

摘　　要：在妇科三大恶性肿瘤中,卵巢癌(OC)的致死率居于首位。手术联合化疗是OC的主要治疗方式,但约有70%的患者治疗后病情会复发,最终发生耐药,而这对于患者的后续治疗来说尤为关键,关乎着患者的生存期及生活质量。本文主要总结了铂耐药卵巢癌(CROC)的治疗进展。Among the three major gynecological malignancies,ovarian cancer(OC)has the highest mortality rate.Surgery combined with chemotherapy is the main treatment method for OC,but about 70%of patients will relapse after treatment and eventually develop drug resistance,which is particularly critical for the follow-up treatment of patients,and is related to the survival period and quality of life of patients.This article summarizes the progress in the t reatment of platinum-resistant ovarian cancer(CROC).

关 键 词：铂耐药 卵巢癌 靶向治疗 精准医疗 

分 类 号：R737.31[医药卫生—肿瘤]